Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)Long-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Savara (SVRA) Long-Term Debt Issuances (2016 - 2025)

Savara (SVRA) reported Long-Term Debt Issuances of $29.6 million for Q1 2025, up 34721.18% on a QoQ basis from $85000.0 in Q4 2016.

Savara (SVRA) has 2 years of Long-Term Debt Issuances data on file, last reported at $29.6 million in Q1 2025.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $29.6 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $29.6 million (changed N/A YoY) and the FY2025 annual result came in at $29.6 million, changed N/A from the prior year.
  • Long-Term Debt Issuances advanced to $29.6 million in Q1 2025 per SVRA's latest filing, from $85000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $29.6 million in Q1 2025 and bottomed at $29.6 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 29.60 Mn
Mar 31, 2025 29.60 Mn
Dec 31, 2016 85,000.00
Dec 31, 2016 85,000.00